Clinical trial

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

NCT03593590

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2018-11-12

PhaseN/A

Study timeline

Study start (actual)2018-11-12Date precision: day

Registry last updated2026-02-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

OcrelizumabDRUG · verified · RxNorm: ocrelizumab

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

SofiaBulgaria8 ValenciaSpain3 SevilleSpain3 BrusselsBelgium3 BratislavaSlovakia3 CairoEgypt3 MilanLombardy, Italy3 BarcelonaSpain2 WarsawPoland2 IstanbulTurkey (Türkiye)2 BucharestRomania2 KatowicePoland2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03593590 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.